Role of other biologics such as anti-17 antibodies (secukinumab), anti-IL-12/23 antibodies (ustekinumab), anti-CD-20 antibodies (rituximab), anti-B-cell activating factor (belimumab), anti-CD80, and anti-CD86 receptors (abatacept) are also acknowledged for RA therapeutics [75]. Here, TNFSF13B is linked to rheumatoid arthritis.